Previous 10 | Next 10 |
2024-02-07 08:06:56 ET More on Alector Alector: Q4 2024 Data Release Could Provide Major Shift For Valuation Alector: Good Data, Huge Cash, No Near Term Catalyst Stifel upgrades Alector to buy, stock rallies 18% Seeking Alpha’s Quant Rating on Alector ...
-Latozinemab is the most advanced progranulin-elevating candidate in development for FTD-GRN and has now become the first investigational medicine to receive a Breakthrough Therapy Designation for the treatment of FTD-GRN- SOUTH SAN FRANCISCO, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Ale...
2024-01-23 07:32:27 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Some of the worst and most deadly diseases affect our brains. In multiple sclerosis, the immune system “causes communication problems between your brain and the rest of your body,”...
SOUTH SAN FRANCISCO, Calif., Jan. 19, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the closing of its underwritten public offering of shares of its common stock. Alector sold 10,869,566 shares of its com...
2024-01-17 17:32:22 ET Summary Alector, Inc. expects results from its phase 2 INVOKE-2 study, using AL002 for the treatment of patients with Alzheimer's disease, in Q4 of 2024. IND clearance received to begin a phase 2 study using AL101 for the treatment of patients with Alzheimer...
2024-01-17 09:37:51 ET More on Alector Alector: Good Data, Huge Cash, No Near Term Catalyst Stifel upgrades Alector to buy, stock rallies 18% Alector GAAP EPS of -$0.53 beats by $0.14, revenue of $9.11M misses by $0.86M For further details see: Alector do...
SOUTH SAN FRANCISCO, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the pricing of an underwritten public offering of 10,869,566 shares of its common stock for total gross proceeds of $75 ...
2024-01-16 16:05:26 ET More on Alector Stifel upgrades Alector to buy, stock rallies 18% Alector GAAP EPS of -$0.53 beats by $0.14, revenue of $9.11M misses by $0.86M For further details see: Alector intends to conduct a public offering of its shares
2024-01-16 11:12:10 ET Summary Alector's stock has traded mostly sideways, down 18% from last year, despite having a promising late-stage CNS pipeline, loads of cash, and two big partnerships. The company has trimmed down its pipeline from 9 programs to 3, but this is a good thing...
2023-12-14 15:01:02 ET More on Alector Alector: Milestone Uncertainty Plus Lack Of Product Revenue Alector GAAP EPS of -$0.53 beats by $0.14, revenue of $9.11M misses by $0.86M Alector achieves target enrollment for Phase 3 dementia study Seeking Alpha’...
News, Short Squeeze, Breakout and More Instantly...
--INVOKE-2 is the first global Phas e 2 trial evaluating the safety and efficacy of a TREM2 agonist, AL002, in slowing disease progression in individuals with early Alzheimer’s disease (AD)-- --Baseline characteristics data for the INVOKE-2 study confirm a representative stud...
SOUTH SAN FRANCISCO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced presentations related to the Company’s TREM2 and progranulin programs at the upcoming Alzheimer's Associatio...
SOUTH SAN FRANCISCO, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in a corporate presentation at the H.C. Wainwright 5 th Annual Neuro Pers...